Is Abeona Therapeutics Inc (ABEO) overvalued? · rev $3.5M
Abeona Therapeutics Inc (ABEO) is a biotechnology company listed on US.
This page asks whether Abeona Therapeutics Inc (ABEO) looks expensive on cached numbers — not a short thesis.
Latest reported ABEO revenue for 2023-12-31 was $3.5M. Net income was -$54.2M. Revenue was up 147.5% from 2022-12-31 to 2023-12-31. ABEO currently screens at market cap $301.8M.
ABEO currently screens at market cap $301.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ABEO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ABEO stock page for the full model, not this heading.
Not investment advice.